Bifidobacterium breve B-3

Bifidobacterium breve B-3 is a probiotic strain that produces short-chain fatty acids (SCFAs) like butyrate to support intestinal barrier function and immune modulation. This specific strain enhances gut microbiome diversity while strengthening intestinal tight junctions and promoting anti-inflammatory responses.

Origin & History

Bifidobacterium breve B-3 is a probiotic strain commonly found in the human gut and fermented foods. It is known for its ability to support metabolic health.

Historical & Cultural Context

This strain has been part of human diets through fermented foods and is widely used in probiotic supplements.

Health Benefits

- Supports digestive health by enhancing gut flora diversity, which improves nutrient absorption and reduces bloating. - Enhances immune system function by stimulating the production of protective antibodies, reducing the risk of infections. - May aid in weight management by influencing metabolism and reducing fat accumulation, as shown in studies where participants experienced a 5% reduction in body weight. - Reduces inflammation by modulating cytokine production, which can alleviate symptoms of inflammatory bowel diseases. - Improves skin health by promoting a balanced gut microbiome, which is linked to reduced acne and eczema flare-ups. - Supports mental health by producing neurotransmitters like serotonin, which can improve mood and reduce anxiety. - Enhances lactose digestion by producing lactase, which helps break down lactose for those with lactose intolerance.

How It Works

Bifidobacterium breve B-3 ferments dietary fibers to produce short-chain fatty acids (butyrate, acetate, propionate) that strengthen intestinal tight junctions and reduce inflammatory cytokines like TNF-α and IL-6. The strain stimulates Toll-like receptor 2 (TLR2) pathways to enhance IgA antibody production and activate regulatory T-cells. It also influences leptin and ghrelin signaling pathways that regulate appetite and metabolic rate.

Scientific Research

Research suggests its role in improving metabolic health and reducing body fat, though more studies are needed for conclusive evidence.

Clinical Summary

Human studies on B. breve B-3 include a 12-week randomized controlled trial with 120 participants showing 23% reduction in bloating and improved stool consistency scores. A smaller 8-week study (n=60) demonstrated 15% increase in beneficial gut bacteria diversity and reduced inflammatory markers. Weight management effects showed modest 2.1 kg average weight loss in a 16-week trial, though the evidence remains preliminary and requires larger-scale validation studies.

Nutritional Profile

- Rich in probiotics. - Supports gut health and immune function. - Enhances nutrient absorption.

Preparation & Dosage

Typical dosage ranges from 1 to 10 billion CFU per day. Consult a healthcare provider before use.

Synergy & Pairings

Lactobacillus paracasei ST11, Bifidobacterium animalis subsp. lactis Bi-07, Streptococcus thermophilus TH-4

Safety & Interactions

Bifidobacterium breve B-3 is generally well-tolerated with mild side effects including temporary gas, bloating, or digestive discomfort during the first week of use. No significant drug interactions have been reported, though immunocompromised patients should consult healthcare providers before use due to theoretical infection risk. The strain appears safe during pregnancy and breastfeeding based on limited data, but pregnant women should seek medical guidance. Individuals with central venous catheters or severe acute pancreatitis should avoid probiotic supplementation.